A total of 884 patients were identified: 639 (72.3%) in the RT cohort & 245 (27.7%) in the CRT cohort.
Patient cohorts were well-balanced in key socioeconomic (race, sex, insurance, income & education) & clinical characteristics (tumor site, grade, size & surgical margin status). Patients in the CRT arm were more likely to be younger (≤50) (44.9% vs 20.8%), have a Charlson-Deyo [CD] score of 0 (85.7% vs 79.3%) & have synovial sarcoma histology (19.6% vs 2.8%).
The unadjusted 5-year KM OS was significantly higher in the CRT vs RT cohort: 72.0% vs 56.1% on univariate (p<0.0001) & multivariate analysis (Hazard Ratio [HR]: 0.57; 95% Confidence Interval [CI]: 0.41-0.78; p<0.001) even after adjusting for age, race, income, CD score, histology, tumor size, tumor grade & primary site (lower extremity; upper extremity; trunk).
PSM identified evenly matched cohorts of 212 patients each with respect to age, income, CD score, histology, grade, tumor size & primary site. The adjusted 5-year KM OS was significantly higher in the CRT vs RT cohort: 69.8% vs 55.4%. The addition of neoadjuvant C remained prognostic for OS on PSM analysis (HR: 0.56 [0.39-0.83], p=0.003).
There were no statistical differences in the mean surgical inpatient stay (3.8 vs 4.3 days), 30-day unplanned readmission rate (5.0% each), or 90-day mortality (2.0% vs 1.2%) between the RT vs CRT cohorts.